Incidence of complications associated to bile duct stents, in patients with advanced cancer: a single-center experience

被引:1
作者
Corbera, Alex [1 ,2 ]
Rios-Hoyo, Alejandro [1 ]
Visa, Laura [1 ,2 ]
Casadevall, David [1 ,2 ]
Ilzarbe, Lucas [3 ]
Barranco, Luis [3 ]
Radosevic, Aleksandar [4 ]
Servitja, Sonia [1 ,2 ]
机构
[1] Hosp del Mar, Med Oncol Dept, CIBERONC, Barcelona 08003, Spain
[2] IMIM Inst Hosp del Mar Invest Med, Canc Res Program, Barcelona, Spain
[3] Hosp del Mar, Gastroenterol Dept, Barcelona 08003, Spain
[4] Hosp del Mar, Radiol Dept, Barcelona 08003, Spain
关键词
Hyperbilirubinemia; Pancreatic cancer; Biliary duct cancer; Palliative care; Biliary stent; BILIARY; MANAGEMENT;
D O I
10.1007/s00520-021-06737-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Pancreatic cancer (PCa) and biliary tract carcinomas (BTCa) have high morbidity and mortality rates. Bile duct obstruction (BDO) develops in approximately 65-75% of PCa at diagnosis, delaying the administration of optimal treatment. In patients not candidates for surgery, BDO is usually treated through the endoscopy-guided placement of self-expanding stents in the bile duct. Methods In this retrospective study, we sought to describe clinical characteristics and outcomes of a cohort of patients with BDO of malignant origin who underwent biliary stent placement (BSP), with a special focus regarding complications developed after the procedure. Patients with PCa, BTCa, colon cancer, lung cancer, gastric cancer, and ovarian cancer who underwent BSP from 2014 to April 2019 at our institution were included in this cohort. Demographic and clinicopathologic characteristics were collected. Statistical analysis stratified according to ECOG performance status. Specific information regarding stent material (metallic vs. plastic), as well as incidence and type of complications derived from BSP, was also recorded. Results One hundred fifteen patients were included. The median age was 72 years. Sixty-six patients (57%) had PCa. All patients presented hyperbilirubinemia, which decreased after the procedure in 111 (96%) patients. Complications were observed in 44 (38%) patients, most of which 33 (75%) were infections. The median time to the complication was 1 month. The mean overall survival (OS) in our study was 20.3 weeks. Conclusion BSP effectively decreased hyperbilirubinemia in patients with BDO; however, the procedure associated a significant rate of infectious complications, which can further compromise an effective anti-cancer therapy as well as optimal palliative strategies.
引用
收藏
页码:4373 / 4378
页数:6
相关论文
共 11 条
  • [1] SYMPTOM RELIEF AND QUALITY-OF-LIFE AFTER STENTING FOR MALIGNANT BILE-DUCT OBSTRUCTION
    BALLINGER, AB
    MCHUGH, M
    CATNACH, SM
    ALSTEAD, EM
    CLARK, ML
    [J]. GUT, 1994, 35 (04) : 467 - 470
  • [2] Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017
    Dumonceau, Jean-Marc
    Tringali, Andrea
    Papanikolaou, Ioannis S.
    Blero, Daniel
    Mangiavillano, Benedetto
    Schmidt, Arthur
    Vanbiervliet, Geoffroy
    Costamagna, Guido
    Deviere, Jacques
    Garcia-Cano, Jesus
    Gyoekeres, Tibor
    Hassan, Cesare
    Prat, Frederic
    Siersema, Peter D.
    van Hooft, Jeanin E.
    [J]. ENDOSCOPY, 2018, 50 (09) : 910 - 930
  • [3] Endoscopic biliary stenting for unresectable malignant hilar obstruction
    Fukasawa M.
    Takano S.
    Shindo H.
    Takahashi E.
    Sato T.
    Enomoto N.
    [J]. Clinical Journal of Gastroenterology, 2017, 10 (6) : 485 - 490
  • [4] Plastic biliary stent patency in patients with locally advanced pancreatic adenocarcinoma receiving downstaging chemotherapy
    Ge, Phillip S.
    Hamerski, Christopher M.
    Watson, Rabindra R.
    Komanduri, Srinadh
    Cinnor, Birtukan B.
    Bidari, Kiran
    Klapman, Jason B.
    Lin, Cui L.
    Shah, Janak N.
    Wani, Sachin
    Donahue, Timothy R.
    Muthusamy, V. Raman
    [J]. GASTROINTESTINAL ENDOSCOPY, 2015, 81 (02) : 360 - 366
  • [5] Multidisciplinary Cancer Management: A Systems-Based Approach to Deliver Complex Care
    Jacobson, Joseph O.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2010, 6 (06) : 274 - 275
  • [6] Percutaneous Palliation of Pancreatic Head Cancer: Randomized Comparison of ePTFE/FEP-Covered Versus Uncovered Nitinol Biliary Stents
    Krokidis, Miltiadis
    Fanelli, Fabrizio
    Orgera, Gianluigi
    Tsetis, Dimitrios
    Mouzas, Ioannis
    Bezzi, Mario
    Kouroumalis, Elias
    Pasariello, Roberto
    Hatzidakis, Adam
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2011, 34 (02) : 352 - 361
  • [7] Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy
    Lamarca, Angela
    Rigby, Christina
    McNamara, Mairead G.
    Hubner, Richard A.
    Valle, Juan W.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (26) : 6065 - 6075
  • [8] Medica S., 2019, REDECAN GLOB CANC OB, V19, P1
  • [9] Parkin D. M., 1999, CA Cancer J. Clin, V49, P33, DOI [DOI 10.3322/CANJCLIN.49.1.33, 10.3322/canjclin.49.1.33, DOI 10.3322/CAAC.21492]
  • [10] Ruppert L. M., 2016, CHANG BRAIN IMPACT D, P189, DOI [10.1007/978-0-387-98188-8_9, DOI 10.1007/978-0-387-98188-8_9]